High Prevalence of Activated Intraepithelial Cytotoxic T Lymphocytes and Increased Neoplastic Cell Apoptosis in Colorectal Carcinomas with Microsatellite Instability
Overview
Authors
Affiliations
Microsatellite instability (MSI) characterizes colorectal carcinomas (CRCs) in hereditary nonpolyposis colorectal cancer (HNPCC) syndrome and a proportion of sporadic CRCs. These MSI+ CRCs share several clinicopathological features, including a reputation for better survival rates than MSI- cases and a pronounced stromal inflammatory reaction of still undefined nature. In the present study, the presence, spatial distribution, and activation status of infiltrating cytotoxic effectors were investigated comparatively in 18 MSI+ and 37 MSI- CRCs by immunohistochemistry. The frequency of apoptosis was also evaluated by morphology and in situ end-labeling. MSI+ cases carried significantly higher numbers of cytotoxic lymphocytes infiltrating within neoplastic epithelial structures, as shown by immunostaining for CD3 (15.1 +/- 6.2 versus 4.6 +/- 4.1, P < 0.001), CD8 (13 +/- 6.4 versus 3.7 +/- 3.8, P < 0.001), and TIA-1 (11.2 +/- 6.5 versus 1.9 +/- 1.7, P < 0.001). These cytotoxic effectors were globally more activated in MSI+ than in MSI- tumors, as revealed by the expression of granzyme B (5.3 +/- 4.5 versus 0.6 +/- 1.3, P < 0.001). In MSI+ CRCs, the number of intraepithelial activated cytotoxic lymphocytes was significantly correlated with the proximal location of the tumor, a poorly differentiated phenotype, and the presence of peritumor lymphoid nodules. Multivariate analysis revealed that MSI was the major determinant of the presence of activated cytotoxic intraepithelial lymphocytes. Moreover, MSI+ CRCs also showed a significantly higher percentage of tumor cells undergoing apoptotic cell death (4.1 +/- 2.1 versus 2.6 +/- 1.1, P < 0.0001, by the TUNEL method), often located in close proximity of activated cytotoxic lymphocytes. These results are consistent with the presence of anti-tumor cytotoxic immune responses in most of MSI+ CRCs, a phenomenon that may at least in part contribute to the survival advantage ascribed to these patients.
Wang Q, Yu M, Zhang S Front Immunol. 2025; 15:1440830.
PMID: 39877377 PMC: 11772360. DOI: 10.3389/fimmu.2024.1440830.
Genomic instability as a driver and suppressor of anti-tumor immunity.
Requesens M, Foijer F, Nijman H, de Bruyn M Front Immunol. 2024; 15:1462496.
PMID: 39544936 PMC: 11562473. DOI: 10.3389/fimmu.2024.1462496.
Gharib E, Robichaud G Int J Mol Sci. 2024; 25(17).
PMID: 39273409 PMC: 11395697. DOI: 10.3390/ijms25179463.
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors.
Amodio V, Vitiello P, Bardelli A, Germano G Br J Cancer. 2024; 131(10):1576-1590.
PMID: 39271762 PMC: 11554791. DOI: 10.1038/s41416-024-02848-8.
Immune checkpoint inhibitors in colorectal cancer: limitation and challenges.
Yan S, Wang W, Feng Z, Xue J, Liang W, Wu X Front Immunol. 2024; 15:1403533.
PMID: 38919624 PMC: 11196401. DOI: 10.3389/fimmu.2024.1403533.